Disease Domain | Count |
---|---|
Neoplasms | 4 |
Endocrinology and Metabolic Disease | 2 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 2 |
Radionuclide Drug Conjugates (RDC) | 1 |
Small molecule drug | 1 |
Therapeutic radiopharmaceuticals | 1 |
Target |
Mechanism HGF inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GDF15 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date11 Jan 2024 |
Sponsor / Collaborator |
Start Date05 Jan 2024 |
Sponsor / Collaborator |
Start Date13 Jun 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tivozanib ( PDGFRβ x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit ) | Renal Cell Carcinoma More | Approved |
Ficlatuzumab ( HGF ) | Squamous cell carcinoma of head and neck metastatic More | Phase 3 |
Rilogrotug ( GDF15 ) | Cachexia More | Phase 1 |
225Ac-HER3 ( HER3 ) | Solid tumor More | Preclinical |
MP-412 ( EGFR x HER2 ) | Refractory Malignant Solid Neoplasm More | Discontinued |